Products & Capabilities

ScinoPharm is expanding its chemistry-based API business into the biopharmaceutical area. ScinoPharm’s Biotech group has developed the cell lines and process technologies for the following recombinant proteins.

ScinoPharm is currently focusing on development of cell lines and process technologies for more than 10 biosimilars of monoclonal antibodies, including:

• Trastuzumab
• Bevacizumab
• Rituximab
• Cetuximab
• Adalimumab

ScinoPharm over the years has established the following core expertise and capabilities:

• Gene cloning
• Protein expression
• Fermentation and cell culture
• Recovery and purification
• Product characterization
• Bioassay

On protein expression, ScinoPharm has considerable experiences in E. coli, Pichia, and CHO systems. Furthermore, ScinoPharm has developed platform technologies for screening and selection of high producing clones for production of biosimilar monoclonal antibodies.